{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:59:52Z","timestamp":1791568792481,"version":"4.3.4"},"reference-count":131,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Prostate-specific membrane antigen (PSMA) targeting agents have been the cornerstone of advanced prostate cancer (PCa) management in theranostics due to their high sensitivity for detecting and treating metastatic disease. However, approximately one-third of metastatic castration-resistant PCa (mCRPC) lesions may exhibit low or absent PSMA expression due to tumor heterogeneity, prior androgen deprivation therapy, or loss of androgen receptor expression, subsequently altering their response to PSMA-targeted therapy. The molecular and biological mechanisms underlying PSMA downregulation remain elusive but may include neuroendocrine differentiation or epithelial-to-mesenchymal transition (EMT). This review addresses this knowledge gap by examining recent preclinical and clinical evidence on novel radiotracers with the potential to provide alternative strategies beyond PSMA for imaging and treating PCa. The diagnostic performance and therapeutic potential of three emerging radiotracer classes are discussed, including gastrin-releasing peptide receptor (GRPR) ligands, androgen receptor (AR) ligands, and amino acid analogs. This article further highlights the complementary roles of these radiotracers along with their utility in specific patient populations, such as those with low prostate-specific antigen (PSA), biochemical recurrence (BCR), or confirmed PSMA-negative disease. For instance, GRPR-targeted radiotracers have achieved sensitivity of up to 88% and specificity of up to 90% for detecting primary tumors in PCa. The radiolabeled androgen agonist, fluorine-18 (18F)-fluoro-5\u03b1-dihydrotestosterone (FDHT), has demonstrated 98% true-positive rate in predicting lesions on positron emission tomography (PET) scans of mCRPC patients. On the other hand, the synthetic amino acid analog 18F-fluciclovine demonstrated a lesion detection rate of 84% for PSA levels at or above 5, and 62.5% for PSA levels ranging from 0.7 to less than 1. This review concludes with future directions on the paradigm of multi-tracer and dual-targeting strategies, which can effectively address challenges associated with PCa tumor heterogeneity and facilitate personalized approaches in theranostics.<\/jats:p>","DOI":"10.3390\/diagnostics15212737","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:02:01Z","timestamp":1761670921000},"page":"2737","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7111-5268","authenticated-orcid":false,"given":"Farzana Z.","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, Division of Nuclear Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pej\u010di\u0107, T., Todorovi\u0107, Z., \u0110ura\u0161evi\u0107, S., and Popovi\u0107, L. (2023). Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032939"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/1568009617666170209093101","article-title":"Optimal Management of Prostate Cancer Based on its Natural Clinical History","volume":"18","author":"Facchini","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Borea, R., Favero, D., Miceli, A., Donegani, M.I., Raffa, S., Gandini, A., Cremante, M., Marini, C., Sambuceti, G., and Zanardi, E. (2022). Beyond the Prognostic Value of 2-[(18)F]FDG PET\/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management. Diagnostics, 12.","DOI":"10.3390\/diagnostics12030581"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00117-020-00716-z","article-title":"Multiparametric magnetic resonance imaging and multiparametric magnetic resonance imaging-guided biopsy in the diagnostic pathway of prostate cancer","volume":"60","author":"Chaloupka","year":"2020","journal-title":"Radiologe"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fonc.2018.00653","article-title":"New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen","volume":"8","author":"Cimadamore","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1758835919876828","DOI":"10.1177\/1758835919876828","article-title":"Guiding management of therapy in prostate cancer: Time to switch from conventional imaging to PSMA PET?","volume":"11","author":"Alipour","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00259-011-1775-3","article-title":"Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts","volume":"38","author":"Schroeder","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00259-006-0347-4","article-title":"DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours","volume":"34","author":"Zhang","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","first-page":"1144","article-title":"177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer","volume":"47","author":"Lantry","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00259-010-1388-2","article-title":"A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues","volume":"37","author":"Schroeder","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, L., Chen, C.C., Zhang, Z., Kuo, H.T., Zhang, C., Colpo, N., Merkens, H., B\u00e9nard, F., and Lin, K.S. (2024). Synthesis and Evaluation of Novel (68)Ga-Labeled [D-Phe(6),Leu(13)\u03c8Thz(14)]bombesin(6-14) Analogs for Cancer Imaging with Positron Emission Tomography. Pharmaceuticals, 17.","DOI":"10.3390\/ph17050621"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2191-219X-4-13","article-title":"Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)","volume":"4","author":"Kampmeier","year":"2014","journal-title":"EJNMMI Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2967\/jnumed.110.082826","article-title":"In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer","volume":"52","author":"Lears","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00259-014-2830-7","article-title":"89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer","volume":"41","author":"Beylergil","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.apradiso.2016.01.006","article-title":"Imaging quality of 44Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET","volume":"110","author":"Bunka","year":"2016","journal-title":"Appl. Radiat. Isot."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/21655979.2021.2016086","article-title":"Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes","volume":"13","author":"Hong","year":"2022","journal-title":"Bioengineered"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"Wright","year":"1995","journal-title":"Urol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1538507","DOI":"10.3389\/fmed.2025.1538507","article-title":"Study of predictive factors for response to (177)LU-PSMA in patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Peslier","year":"2025","journal-title":"Front. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA Ligands for PET Imaging of Prostate Cancer","volume":"58","author":"Schwarzenboeck","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"von Stauffenberg, F., Poyet, C., Beintner-Skawran, S., Maurer, A., and Schmid, F.A. (2024). Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers, 16.","DOI":"10.3390\/cancers16244263"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-Based [(18)F]DCFPyL PET\/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.121.263440","article-title":"Utility of (18)F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology","volume":"63","author":"Langbein","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dondi, F., Albano, D., Bertagna, F., and Treglia, G. (2022). Bone Scintigraphy versus PSMA-Targeted PET\/CT or PET\/MRI in Prostate Cancer: Lessons Learned from Recent Systematic Reviews and Meta-Analyses. Cancers, 14.","DOI":"10.3390\/cancers14184470"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: A prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/bjr\/tqae092","article-title":"Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands","volume":"97","author":"Naik","year":"2024","journal-title":"Br. J. Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hameed, M.Y., Gul, M., Chaudhry, A., Muzaffar, H., Sheikh, M., Chee, W., Ayyash, S., Ayyash, J., Al-Hindi, M., and Shahare, H. (2024). From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer. Cancers, 16.","DOI":"10.3390\/cancers16173039"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Eder, M. (2022). [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals, 15.","DOI":"10.3390\/ph15101292"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dorff, T.B., Fanti, S., Farolfi, A., Reiter, R.E., Sadun, T.Y., and Sartor, O. (2019). The evolving role of prostate-specific membrane antigen-based diagnostics and therapeutics in prostate cancer. American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology Annual Meeting.","DOI":"10.1200\/EDBK_239187"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/acs.jmedchem.4c02768","article-title":"PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC)","volume":"68","author":"Jin","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JCO.2022.40.6_suppl.167","article-title":"Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)","volume":"40","author":"Zhang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e162907","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.116.173757","article-title":"Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis","volume":"57","author":"Rahbar","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","article-title":"Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617","volume":"44","author":"Ahmadzadehfar","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: Underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.22784","article-title":"Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer","volume":"74","author":"Eder","year":"2014","journal-title":"Prostate"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","article-title":"Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis","volume":"15","author":"Mannweiler","year":"2009","journal-title":"Pathol. Oncol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and Biological Features of Neuroendocrine Prostate Cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bju.15621","article-title":"The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol","volume":"130","author":"Pouliot","year":"2022","journal-title":"BJU Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2024.42.4_suppl.31","article-title":"Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Pouliot","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","article-title":"Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study","volume":"65","author":"Pouliot","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_50","first-page":"416","article-title":"Safety and Therapeutic Efficacy of 225Ac-DOTATATE Targeted Alpha Therapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors Stable or Refractory to 177Lu-DOTATATE PRRT","volume":"61","author":"Bal","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_51","first-page":"202","article-title":"Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression","volume":"2","author":"Grant","year":"2013","journal-title":"Transl. Androl. Urol."},{"key":"ref_52","first-page":"S13","article-title":"Overview of prostate-specific membrane antigen","volume":"6","author":"Chang","year":"2004","journal-title":"Rev. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-cancerbio-030518-055425","article-title":"The Epithelial-to-Mesenchymal Transition (EMT) in Development and Cancer","volume":"4","author":"Francou","year":"2020","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of Androgen Receptor in Prostate Cancer: A Review","volume":"37","author":"Fujita","year":"2019","journal-title":"World J. Mens. Health"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kairemo, K., and Hodolic, M. (2023). Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098235"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3892\/ijo.2012.1649","article-title":"Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells","volume":"41","author":"Zhang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00259-019-04581-4","article-title":"The effect of androgen deprivation therapy on (68)Ga-PSMA tracer uptake in non-metastatic prostate cancer patients","volume":"47","author":"Onal","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.gendis.2019.10.018","article-title":"Epigenetic regulation of prostate cancer","volume":"7","author":"Wang","year":"2020","journal-title":"Genes. Dis."},{"key":"ref_62","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, R., Soza-Ried, C., Iagaru, A., Stephens, A., M\u00fcller, A., Schieferstein, H., Sandoval, C., Amaral, H., and Kramer, V. (2024). Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2\u2014A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11. Cancers, 16.","DOI":"10.3390\/cancers16010173"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","article-title":"Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors","volume":"20","author":"Baratto","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14737159.2022.2145187","article-title":"Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: From pre-clinical studies to translational perspectives","volume":"22","author":"Gorica","year":"2022","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2967\/jnumed.107.045054","article-title":"Bombesin receptor antagonists may be preferable to agonists for tumor targeting","volume":"49","author":"Cescato","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2967\/jnumed.117.197624","article-title":"Prospective Evaluation of (68)Ga-RM2 PET\/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging","volume":"59","author":"Minamimoto","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.semnuclmed.2025.01.001","article-title":"Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review","volume":"55","author":"Mohseninia","year":"2025","journal-title":"Semin. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","article-title":"GRPr Antagonist 68Ga-SB3 PET\/CT Imaging of Primary Prostate Cancer in Therapy-Na\u00efve Patients","volume":"62","author":"Bakker","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pros.20957","article-title":"Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer","volume":"69","author":"Ananias","year":"2009","journal-title":"Prostate"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","article-title":"In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548","volume":"19","author":"Jambor","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2967\/jnumed.124.267881","article-title":"Utility of (64)Cu-Sarcophagine-Bombesin PET\/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET\/CT","volume":"65","author":"Li","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mansi, R., Nock, B.A., Dalm, S.U., Busstra, M.B., van Weerden, W.M., and Maina, T. (2021). Radiolabeled Bombesin Analogs. Cancers, 13.","DOI":"10.3390\/cancers13225766"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.122.263971","article-title":"Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer","volume":"63","author":"Duan","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_76","first-page":"55","article-title":"Prostate specific membrane antigen- a target for imaging and therapy with radionuclides","volume":"9","author":"Bouchelouche","year":"2010","journal-title":"Discov. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pros.22743","article-title":"Early over-expression of GRP receptors in prostatic carcinogenesis","volume":"74","author":"Waser","year":"2014","journal-title":"Prostate"},{"key":"ref_78","first-page":"P1089","article-title":"Intraindividual comparison of [68Ga]Ga-RM2 and [68Ga]Ga-PSMA PET\/CT in patients with mCRPC in a theranostic setting","volume":"64","author":"Kurth","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2967\/jnumed.115.168393","article-title":"Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in Patients with Biochemically Recurrent Prostate Cancer","volume":"57","author":"Minamimoto","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1199432","DOI":"10.3389\/fonc.2023.1199432","article-title":"GRPR versus PSMA: Expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches","volume":"13","author":"Verhoeven","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Rueda, S., Garc\u00eda-P\u00e9rez, O., Luna-Guti\u00e9rrez, M., Ocampo-Garc\u00eda, B., Santos-Cuevas, C., Ram\u00edrez-Nava, G., Vargas-Ahumada, J., Azor\u00edn-Vega, E., Ferro-Flores, G., and Mel\u00e9ndez-Alafort, L. (2024). Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111358"},{"key":"ref_83","first-page":"952","article-title":"Preliminary evaluation of tumor uptake and laboratory parameters after a single dose of Lu-177-RM2 radioligand therapy in metastatic castrate-resistant prostate cancer","volume":"46","author":"Kramer","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2967\/jnumed.112.112169","article-title":"Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin","volume":"54","author":"Dumont","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bju.12594","article-title":"Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues","volume":"113","author":"Ischia","year":"2014","journal-title":"BJU Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: A radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00259-005-1764-5","article-title":"Positron tomographic assessment of androgen receptors in prostatic carcinoma","volume":"32","author":"Dehdashti","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-11-0316","article-title":"Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen","volume":"2","author":"Ulmert","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.109.066159","article-title":"Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET","volume":"51","author":"Beattie","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_92","first-page":"1009","article-title":"Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons","volume":"37","author":"Bonasera","year":"1996","journal-title":"J. Nucl. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/jm00005a009","article-title":"Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: Preparation via halofluorination-reduction, receptor binding, and tissue distribution","volume":"38","author":"Choe","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Montironi, R., Cimadamore, A., Lopez-Beltran, A., Scarpelli, M., Aurilio, G., Santoni, M., Massari, F., and Cheng, L. (2020). Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells, 9.","DOI":"10.3390\/cells9051073"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Katzenellenbogen, J.A. (2020). PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging. Cancers, 12.","DOI":"10.3390\/cancers12082020"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2967\/jnumed.122.264981","article-title":"Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Na\u00efve Prostate Cancer","volume":"64","author":"Wasinger","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MOU.0b013e32835483d5","article-title":"Molecular imaging of prostate cancer","volume":"22","author":"Fox","year":"2012","journal-title":"Curr. Opin. Urol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1148\/radiol.13130625","article-title":"Bone metastases in castration-resistant prostate cancer: Associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival","volume":"271","author":"Vargas","year":"2014","journal-title":"Radiology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamaoncol.2017.3588","article-title":"Positron Emission Tomography\/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer","volume":"4","author":"Fox","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1148\/rg.2019180139","article-title":"Review of 18F-Fluciclovine PET for Detection of Recurrent Prostate Cancer","volume":"39","author":"Gusman","year":"2019","journal-title":"RadioGraphics"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ucl.2018.03.015","article-title":"Imaging of Prostate Cancer Using Fluciclovine","volume":"45","author":"Zanoni","year":"2018","journal-title":"Urol. Clin. N. Am."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1148\/radiol.2020191689","article-title":"PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis","volume":"296","author":"Tan","year":"2020","journal-title":"Radiology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13550-019-0518-5","article-title":"Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer","volume":"9","author":"Saarinen","year":"2019","journal-title":"EJNMMI Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nucmedbio.2011.06.008","article-title":"Transport mechanisms of trans-1-amino-3-fluoro [1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells","volume":"39","author":"Oka","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.112.113100","article-title":"Radiolabeled amino acids for oncologic imaging","volume":"54","author":"Huang","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13550-020-00728-9","article-title":"18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy","volume":"10","author":"Malviya","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.semnuclmed.2019.02.004","article-title":"Molecular Imaging for Primary Staging of Prostate Cancer","volume":"49","author":"Pomykala","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","article-title":"The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: A systematic review and meta-analysis","volume":"64","author":"Umbehr","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","article-title":"The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET\/CT in the Detection of Prostate Cancer with Biochemical Recurrence: A Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_110","first-page":"46","article-title":"A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer","volume":"48","author":"Oka","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zanoni, L., Mei, R., Bianchi, L., Giunchi, F., Maltoni, L., Pultrone, C.V., Nanni, C., Bossert, I., Matti, A., and Schiavina, R. (2021). The Role of [(18)F]Fluciclovine PET\/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [(11)C]Choline PET\/CT and Histopathological Analysis. Cancers, 13.","DOI":"10.3390\/cancers13071575"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1148\/rg.2016150059","article-title":"Molecular imaging of prostate cancer","volume":"36","author":"Wibmer","year":"2016","journal-title":"Radiographics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41391-021-00382-9","article-title":"(18)F-Fluciclovine PET\/CT performance in biochemical recurrence of prostate cancer: A systematic review","volume":"24","author":"Efstathiou","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cpet.2022.07.005","article-title":"Prostate Cancer Imaging with 18F-Fluciclovine","volume":"17","author":"Schuster","year":"2022","journal-title":"PET Clin."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ijrobp.2020.01.050","article-title":"Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients with Recurrence of Prostate Cancer: Results from the FALCON Trial","volume":"107","author":"Scarsbrook","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.juro.2018.08.050","article-title":"The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial","volume":"201","author":"Andriole","year":"2019","journal-title":"J. Urol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2967\/jnumed.122.264832","article-title":"Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus (18)F-Fluciclovine PET\/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial","volume":"64","author":"Lawal","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13550-025-01248-0","article-title":"PSMA-expressing, fluciclovine-negative vertebral hemangioma","volume":"15","author":"Eslambolchi","year":"2025","journal-title":"EJNMMI Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s12149-024-01978-6","article-title":"Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Bilgin","year":"2024","journal-title":"Ann. Nucl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41181-025-00332-z","article-title":"Ac-225 radiochemistry through the lens of [(225)Ac]Ac-DOTA-TATE","volume":"10","author":"Hooijman","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-04-1842","article-title":"Prostate stem cell antigen is overexpressed in prostate cancer metastases","volume":"11","author":"Lam","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13000-016-0495-1","article-title":"Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer","volume":"11","author":"Ambrosio","year":"2016","journal-title":"Diagn. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.matbio.2018.08.004","article-title":"Prostate cancer sheds the \u03b1v\u03b23 integrin in vivo through exosomes","volume":"77","author":"Krishn","year":"2019","journal-title":"Matrix Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4161\/cbt.7.11.7218","article-title":"New insights into the role of CXCR4 in prostate cancer metastasis","volume":"7","author":"Gladson","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.4161\/cbt.7.11.6862","article-title":"Tumor cell-specific blockade of CXCR4\/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach","volume":"7","author":"Xing","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00259-019-04355-y","article-title":"Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use","volume":"46","author":"He","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40336-023-00547-7","article-title":"Clinical applications of long axial field-of-view PET\/CT scanners in oncology","volume":"11","author":"Urso","year":"2023","journal-title":"Clin. Transl. Imaging"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","article-title":"Implementing Ac-225 labelled radiopharmaceuticals: Practical considerations and (pre-)clinical perspectives","volume":"9","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41181-018-0038-z","article-title":"Production of novel diagnostic radionuclides in small medical cyclotrons","volume":"3","author":"Synowiecki","year":"2018","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","article-title":"Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I\/II study","volume":"33","author":"Beheshti","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Filippi, L., Urso, L., Schillaci, O., and Evangelista, L. (2023). [(18)F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13152613"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/21\/2737\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:21:13Z","timestamp":1761672073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/21\/2737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":131,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["diagnostics15212737"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15212737","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}